CO6382117A2 - Metodo para clasificar compuestos que interactuan selectivamente con rad9 - Google Patents

Metodo para clasificar compuestos que interactuan selectivamente con rad9

Info

Publication number
CO6382117A2
CO6382117A2 CO11064192A CO11064192A CO6382117A2 CO 6382117 A2 CO6382117 A2 CO 6382117A2 CO 11064192 A CO11064192 A CO 11064192A CO 11064192 A CO11064192 A CO 11064192A CO 6382117 A2 CO6382117 A2 CO 6382117A2
Authority
CO
Colombia
Prior art keywords
cancer
securolide
rad9
hrad9
compounds
Prior art date
Application number
CO11064192A
Other languages
English (en)
Inventor
David Terrero
Garcia Federico Gomez
Original Assignee
Magnachem Int Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magnachem Int Lab Inc filed Critical Magnachem Int Lab Inc
Publication of CO6382117A2 publication Critical patent/CO6382117A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Compuestos naturales y sintéticos de las fórmulas la-le que tienen una estructura de lactona, en particular Securolide, se han determinado que son compuestos anti-tumorales efectivos que se dirigen al gen hrad9 y/o proteína codificada por el mismo o complejo que contiene la proteína y/o el gen p53 y/o proteína. El Securolide es citoselectivo para mutantes de hRad9 con base en estudios conducidos en cepas de levadura de mutante rad9. El Securolide parece que interactúa con el mutante hRad9 en células cancerosas para producir lesiones de DNA las cuales dan por resultado la apoptosis. Los estudios han demostrado que el Securolide es útil para tratar desórdenes de proliferación tal como melanoma, leucemia, cáncer de seno, cáncer de pulmón, cáncer de ovarios, cáncer de colon, cáncer de esófago, cáncer de hígado, y cáncer linfático, y para mitigar el dolor asociado con el cáncer. Otros compuestos efectivos para el tratamiento de cáncer y opcionalmente dolor asociado con el mismo también se pueden identificar usando los mismos ensayos, por ejemplo, mediante la clasificación de eficacia en ensayos que usan levaduras de mutante defectuosas de Rad9 y/o p53.
CO11064192A 2008-10-24 2011-05-24 Metodo para clasificar compuestos que interactuan selectivamente con rad9 CO6382117A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10822408P 2008-10-24 2008-10-24

Publications (1)

Publication Number Publication Date
CO6382117A2 true CO6382117A2 (es) 2012-02-15

Family

ID=41491699

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11064192A CO6382117A2 (es) 2008-10-24 2011-05-24 Metodo para clasificar compuestos que interactuan selectivamente con rad9

Country Status (15)

Country Link
US (2) US8501431B2 (es)
EP (1) EP2350645A2 (es)
JP (1) JP2012507010A (es)
KR (1) KR20110128785A (es)
CN (1) CN102265154A (es)
AU (1) AU2009308423B2 (es)
BR (1) BRPI0920297A2 (es)
CA (1) CA2741526A1 (es)
CL (1) CL2011000912A1 (es)
CO (1) CO6382117A2 (es)
DO (1) DOP2011000111A (es)
IL (1) IL212475A0 (es)
MX (1) MX2011004331A (es)
WO (1) WO2010048616A2 (es)
ZA (1) ZA201103769B (es)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624723A (en) 1947-03-03 1953-01-06 Allied Chem & Dye Corp Lactone derivatives and method of making
US3203953A (en) 1963-01-18 1965-08-31 Ciba Geigy Corp Lactone obtained from helenium sp. and derivatives thereof
US3210377A (en) 1963-06-05 1965-10-05 Olin Mathieson Gamma lactones
US3933771A (en) * 1973-07-16 1976-01-20 Hooker Chemicals & Plastics Corporation Composition of and method of obtaining small particle size polymers and copolymers of vinyl chloride having a fused surface
US4001425A (en) 1974-04-17 1977-01-04 E. I. Du Pont De Nemours And Company Methods of treating hypertension and pharmaceutical compositions comprising 1-tertiary-alkyl-3-(substituted furyl)ureas as antihypertensive agents
JPS5111173B2 (es) 1974-04-25 1976-04-09
JPS51125722A (en) 1975-01-13 1976-11-02 Sumitomo Chem Co Ltd Germicides for industry and their preparation
JPS597713B2 (ja) 1977-12-19 1984-02-20 三井東圧化学株式会社 新規γ↓−ブチロラクトン誘導体とその製造法
JPS56128776A (en) 1980-03-14 1981-10-08 Otsuka Pharmaceut Factory Inc Alpha-methylene gamma-butyrolactone derivative
JPS5899413A (ja) 1981-12-08 1983-06-13 Kanegafuchi Chem Ind Co Ltd 抗炎症剤
JPS6058973A (ja) 1983-09-13 1985-04-05 Mitsubishi Yuka Yakuhin Kk γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤
JPS6226221A (ja) 1985-07-29 1987-02-04 Japan Tobacco Inc 抗変異原性剤
JP2524760B2 (ja) 1987-07-10 1996-08-14 テイカ株式会社 新規抗生物質
JPH01163175A (ja) 1987-12-21 1989-06-27 Ss Pharmaceut Co Ltd フラン−２−オン誘導体
US5242945A (en) 1991-04-12 1993-09-07 American Home Products Corporation Tetronic and thiotetronic acid derivatives as phospholipase a2 inhibitors
EP0534907B1 (en) * 1991-09-26 1998-08-05 Nippon Zoki Pharmaceutical Co., Ltd. The use of furanone derivatives for the prevention or treatment of autoimmune diseases
US5250735A (en) 1992-04-03 1993-10-05 University Of Pittsburgh 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones, 2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and derivatives thereof
CA2168757A1 (en) 1993-09-17 1995-03-23 Robert A. Chrusciel Substituted tetronic acids useful for treating hiv and other retroviruses
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
ATE201397T1 (de) 1994-06-07 2001-06-15 Teijin Ltd Vitamin d3 derivate und ein verfahren zu ihrer herstellung
AUPN191295A0 (en) 1995-03-23 1995-04-27 Unisearch Limited Microbiocide or microbial regulator
US5962460A (en) 1995-06-27 1999-10-05 National Science Council (Taiwan) Antineoplastic α-methylene-γ-butyrolactones
US5646164A (en) 1995-11-14 1997-07-08 National Science Council α-methylene-γ-butyrolactones: new inhibitors of platelet aggregation
ES2251002T3 (es) 1995-11-17 2006-04-16 The Johns Hopkins University Inhibicion de sintasa de acido graso, como medio para reducir la masa adipocita.
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
US5618835A (en) 1996-02-01 1997-04-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
AU6818298A (en) 1997-04-02 1998-10-22 Merck Frosst Canada & Co. Alpha-methylene gamma lactones as selective cyclooxygenase-2 inhibitors
US5905089A (en) 1997-04-14 1999-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of sesquiterpene lactones for treatment of severe inflammatory disorders
AUPP303498A0 (en) 1998-04-17 1998-05-14 Unisearch Limited Inhibition of gram positive bacteria
AU4428899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of cyclooxygenase-2
WO2000058297A2 (en) 1999-03-30 2000-10-05 E.I. Du Pont De Nemours And Company PROCESS FOR THE PREPARATION OF α-METHYLENE LACTONES
US6660511B1 (en) * 2000-03-03 2003-12-09 Rigel Pharmaceuticals, Inc. Methods of screening for modulation of cell cycle
US6686390B2 (en) 2000-05-22 2004-02-03 Dr. Reddy's Laboratories Limited Compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them
JP2002037797A (ja) 2000-07-25 2002-02-06 Kanegafuchi Chem Ind Co Ltd マクロファージ選択的細胞死誘導物質
EP1334358A1 (en) * 2000-10-03 2003-08-13 Regents of the University of California Targeting cells having mad2 mutation for treatment and/or prevention of disease
IL159296A0 (en) * 2001-06-13 2004-06-01 Magnachem Int Lab Inc Lactone formulations and method of use
US20040208944A1 (en) 2002-06-26 2004-10-21 Armand Malnoe Compositions and methods against inflammatory processes
MXPA05001690A (es) * 2002-08-13 2005-10-19 Univ Illinois Estrategia de deteccion para farmacos anticancer.
EP1562930A4 (en) * 2002-11-05 2008-12-10 Magnachem Int Lab Inc SYNTHETIC LACTONE FORMULATIONS AND METHOD OF USE
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
JP4590629B2 (ja) * 2004-08-23 2010-12-01 国立大学法人金沢大学 Ｐｓｆ１遺伝子欠損動物およびその利用方法
JP4560430B2 (ja) * 2005-03-17 2010-10-13 株式会社リコー 画像形成装置、画像印刷システム、プログラムおよび画像合成出力方法
JP2008105963A (ja) * 2006-10-23 2008-05-08 Iwate Univ Ｄｎａ損傷チェックポイント活性化剤

Also Published As

Publication number Publication date
CL2011000912A1 (es) 2011-10-07
ZA201103769B (en) 2012-01-25
US8501431B2 (en) 2013-08-06
US20100137618A1 (en) 2010-06-03
US20140194632A1 (en) 2014-07-10
JP2012507010A (ja) 2012-03-22
AU2009308423A1 (en) 2010-04-29
EP2350645A2 (en) 2011-08-03
WO2010048616A3 (en) 2010-06-10
CA2741526A1 (en) 2010-04-29
DOP2011000111A (es) 2012-01-15
MX2011004331A (es) 2011-09-21
CN102265154A (zh) 2011-11-30
IL212475A0 (en) 2011-06-30
BRPI0920297A2 (pt) 2016-08-02
AU2009308423B2 (en) 2013-08-29
WO2010048616A2 (en) 2010-04-29
KR20110128785A (ko) 2011-11-30

Similar Documents

Publication Publication Date Title
Zucconi et al. Biodeterioration agents dwelling in or on the wall paintings of the Holy Saviour’s cave (Vallerano, Italy)
CY1114340T1 (el) Συνθεσεις και χρησεις για θεραπεια σκληρυνσης κατα πλακας
EA201491418A1 (ru) Рекомбинантные микроорганизмы и способы их применения
CY1119290T1 (el) Μονοκλωνα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
UY30892A1 (es) Inhibidores de la actividad akt
WO2014059424A3 (en) Flexible heat sealable decorative articles and method for making the same
MY177062A (en) Cd37-binding molecules and immunoconjugates thereof
GB2463337A (en) Methods of producing organic products with photosynthetic organisms and products and compositions thereof
NZ598791A (en) Anti-gcc antibody molecules and related compositions and methods
IN2014CN03042A (es)
ECSP10010438A (es) ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS Y METODOS DE USO
CR20110631A (es) Inmunoglobulina con dominio variable dual y usos de la misma
BR112014011331A2 (pt) anticorpos específicos para trop-2 e seus usos
ECSP11011436A (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS Y MÉTODOS DE USO
SV2006002283A (es) Formulaciones
BR112015020517A2 (pt) produto abrasivo, superfície de produto abrasivo, aparelho, uso de um produto abrasivo, e, método para obter um produto abrasivo
SA113340703B1 (ar) سلالة جديدة من بكتيريا Lactobacillus Crispatus
BR112013027641A2 (pt) processo verde para produzir poli-hidroxialcanoatos e produtos químicos com o uso de uma matéria-prima renovável
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
BR112015013928A2 (pt) fabricação de eletrodos tridimensionais com área de superfície elevada
BR112015032334A8 (pt) Processo para revestimento de pelo menos regiões parciais da superfície de um substrato ou para produção de substratos com uma região de superfície
WO2022175255A3 (en) Trispecific antibody targeting bcma, gprc5d, and cd3
PH12019502892A1 (en) Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
CO6382117A2 (es) Metodo para clasificar compuestos que interactuan selectivamente con rad9
WO2014153209A8 (en) Antisense oligonucleotides for treatment of cancer stem cells

Legal Events

Date Code Title Description
FC Application refused